Use of targeted therapy for refractory ALK-positive anaplastic large cell lymphoma as a bridging strategy prior to allogeneic transplantation

被引：0
作者：
R. Ordemann
J. Stöhlmacher
B. Beuthien-Baumann
I. Platzek
J. van den Hoff
F. Kroschinsky
J. M. Middeke
U. Platzbecker
C. Zietz
M. Bornhäuser
G. Ehninger
机构：
[1] University Hospital,Medical Clinic and Policlinic I
[2] University Hospital,Department of Radiation Oncology
[3] Institute of Radiopharmacy,PET Center
[4] Helmholtz-Zentrum Dresden-Rossendorf,Department of Pathology
[5] University Hospital,undefined
来源：
Annals of Hematology | 2013年 / 92卷
关键词：
Anaplastic Lymphoma Kinase; Graft Versus Host Disease; Anaplastic Large Cell Lymphoma; Crizotinib; Brentuximab Vedotin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：125 / 127
页数：2
相关论文
共 16 条
[1]  
Gambacorti-Passerini C(2011)Crizotinib in anaplastic large-cell lymphoma N Engl J Med 364 775-776
[2]  
Messa C(2010)Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer N Engl J Med 363 1693-1703
[3]  
Pogliani EM(2011)Effect of Crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis Lancet Oncol 11 1004-1012
[4]  
Kwak EL(2010)Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas N Engl J Med 363 1812-1821
[5]  
Bang YJ(2011)Current status of allogeneic transplantation for aggressive non-Hodgkin lymphoma Curr Opin Oncol 23 681-691
[6]  
Camidge DR(undefined)undefined undefined undefined undefined-undefined
[7]  
Shaw AT(undefined)undefined undefined undefined undefined-undefined
[8]  
Shaw AT(undefined)undefined undefined undefined undefined-undefined
[9]  
Yeap BY(undefined)undefined undefined undefined undefined-undefined
[10]  
Solomon BJ(undefined)undefined undefined undefined undefined-undefined
12